SCYNEXIS And Hansoh Pharma Announce NMPA Acceptance Of The New Drug Application For Ibrexafungerp In China
Portfolio Pulse from Happy Mohamed
SCYNEXIS, Inc. (NASDAQ:SCYX) and Hansoh Pharmaceutical Group Company Limited (3692.HK) have announced that China's National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for oral ibrexafungerp tablets for the treatment of vulvovaginal candidiasis (VVC) in China. The application is based on positive results from Phase 3 studies. SCYNEXIS entered into an agreement with Hansoh Pharma in February 2021 for the development and commercialization rights for oral ibrexafungerp in the greater China region.
July 20, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SCYNEXIS's new drug application for ibrexafungerp has been accepted by China's NMPA. This could potentially open up a new market for the company and boost its revenues.
The acceptance of the NDA by the NMPA is a positive development for SCYNEXIS. It signifies that the drug has met the necessary criteria for review, bringing it one step closer to approval and commercialization in China. If approved, this could potentially increase the company's revenues by opening up a new market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100